These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
173 related articles for article (PubMed ID: 6172868)
1. New Approaches to the therapy of sickle cell disease. Luskey KL; Schechter AN; Hercules JI Tex Rep Biol Med; 1980-1981; 40():305-12. PubMed ID: 6172868 [No Abstract] [Full Text] [Related]
2. Extracorporeal treatment of erythrocytes in sickle cell anemia: hemoglobin carbamylation. Diederich D; Curran M; Odenbaugh A; Diederich A; Core E Tex Rep Biol Med; 1980-1981; 40():313-22. PubMed ID: 7323976 [No Abstract] [Full Text] [Related]
3. The treatment of sickle cell disease. A historical and chronological literature review of the therapies applied since 1910. Aluoch JR Trop Geogr Med; 1984 Dec; 36(4):S1-26. PubMed ID: 6396910 [TBL] [Abstract][Full Text] [Related]
4. Advances in the understanding of sickle cell anemia. Charache S Hosp Pract (Off Ed); 1986 Feb; 21(2):173-8, 182-90. PubMed ID: 2419352 [No Abstract] [Full Text] [Related]
5. Prevention and treatment of sickle cell crisis by induced hyponatremia. Rosa RM; Bierer B; Thomas R; Stoff JS; Kruskall M; Robinson S; Bunn HF; Epstein FH Trans Assoc Am Physicians; 1980; 93():164-74. PubMed ID: 7245573 [No Abstract] [Full Text] [Related]
6. The treatment of sickle cell anemia with induced hyponatremia. Rosa RM; Bierer BE; Bunn HF; Epstein FH Blood Cells; 1982; 8(2):329-35. PubMed ID: 7159756 [TBL] [Abstract][Full Text] [Related]
7. A view of the current status of antisickling therapy. Brewer GJ Am J Hematol; 1976; 1(1):121-8. PubMed ID: 790948 [No Abstract] [Full Text] [Related]
8. Effects of cetiedil on monovalent cation permeability in the erythrocyte: an explanation for the efficacy of cetiedil in the treatment of sickle cell anemia. Berkowitz LR; Orringer EP Blood Cells; 1982; 8(2):283-8. PubMed ID: 7159752 [TBL] [Abstract][Full Text] [Related]
9. Sickle-cell anemia: molecular and cellular bases of therapeutic approaches (second of three parts). Dean J; Schechter AN N Engl J Med; 1978 Oct; 299(15):804-11. PubMed ID: 692564 [No Abstract] [Full Text] [Related]
10. Cyanate as an inhibitor of red-cell sickling. Cerami A N Engl J Med; 1972 Oct; 287(16):807-12. PubMed ID: 4560520 [No Abstract] [Full Text] [Related]
11. Pathophysiologically based drug treatment of sickle cell disease. Steinberg MH Trends Pharmacol Sci; 2006 Apr; 27(4):204-10. PubMed ID: 16530854 [TBL] [Abstract][Full Text] [Related]
12. Pharmacologic manipulation of fetal hemoglobin levels in sickle cell diseases and thalassemia: promise and reality. Pearson HA Adv Pediatr; 1996; 43():309-34. PubMed ID: 8794181 [No Abstract] [Full Text] [Related]
15. Established and experimental treatments for sickle cell disease. De Franceschi L; Corrocher R Haematologica; 2004 Mar; 89(3):348-56. PubMed ID: 15020275 [TBL] [Abstract][Full Text] [Related]
16. Hydroxyurea therapy: improving the lives of patients with sickle cell disease. Anderson N Pediatr Nurs; 2006; 32(6):541-3. PubMed ID: 17256291 [TBL] [Abstract][Full Text] [Related]
17. Effects of hydroxyurea on the membrane of erythrocytes and platelets in sickle cell anemia. Covas DT; de Lucena Angulo I; Vianna Bonini Palma P; Zago MA Haematologica; 2004 Mar; 89(3):273-80. PubMed ID: 15020264 [TBL] [Abstract][Full Text] [Related]
18. Overview of pathophysiology and rationale for treatment of sickle cell anemia. Rodgers GP Semin Hematol; 1997 Jul; 34(3 Suppl 3):2-7. PubMed ID: 9317195 [TBL] [Abstract][Full Text] [Related]
19. [Hydroxyurea and other agents stimulating synthesis of fetal hemoglobin]. de Montalembert M Pathol Biol (Paris); 1999 Jan; 47(1):55-8. PubMed ID: 10081780 [TBL] [Abstract][Full Text] [Related]
20. New drugs in the treatment of sickle cell anemia. Freedman ML Am J Med Sci; 1973 May; 265(5):371-3. PubMed ID: 4576757 [No Abstract] [Full Text] [Related] [Next] [New Search]